Pearl Therapeutics

31 total trials 30 completed

Pearl Therapeutics sponsors 31 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 30 completed. 12 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Obstructive Pulmonary Disease, with 2 trials.

Trial Pipeline

31 total, page 1 of 1

COMPLETED Phase 2

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

NCT03358147
COMPLETED Phase 1

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

NCT03311373
COMPLETED Phase 1

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

NCT03250182
TERMINATED Phase 3

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

NCT02685293
COMPLETED Phase 3

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

NCT02766608
COMPLETED Phase 3

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

NCT02727660
COMPLETED Phase 3

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

NCT02497001
COMPLETED Phase 3

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT02536508
COMPLETED Phase 3

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

NCT02465567
COMPLETED Phase 2

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
COMPLETED Phase 3

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

NCT02454959
COMPLETED Phase 3

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

NCT02343458
COMPLETED Phase 3

Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

NCT02268396
COMPLETED Phase 2

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT02196077
COMPLETED Phase 1

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

NCT02197975
COMPLETED Phase 1

PK Study of PT003 and PT001 in Japanese Healthy Subjects

NCT02196714
COMPLETED Phase 1

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

NCT02189304
COMPLETED Phase 2

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

NCT02109406
COMPLETED Phase 2

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

NCT02105012
COMPLETED Phase 1

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

NCT01980615
COMPLETED Phase 3

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
COMPLETED Phase 3

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

NCT01854658
COMPLETED Phase 3

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
COMPLETED Phase 2

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01587079
COMPLETED Phase 2

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
COMPLETED Phase 2

PT003 MDI Dose Confirmation Study

NCT01349816
COMPLETED Phase 2

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01350128
COMPLETED Phase 2

PT003 MDI Cardiovascular Safety Study

NCT01349803
COMPLETED Phase 2

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

NCT01349868
COMPLETED Phase 2

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01085045
COMPLETED Phase 1

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00871182

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 12
Phase 3 12

Therapeutic Areas

Chronic Obstructive Pulmonary Disease 2
Chronic Obstructive Pulmonary Disorder 1

What the Pipeline for Pearl Therapeutics Shows

According to the ClinicalTrials.gov registry, Pearl Therapeutics is linked to 31 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 30 are already marked complete, representing roughly 97% of the total.

The phase mix for Pearl Therapeutics reports 12 late-stage studies (Phase 3 and Phase 4 combined) and 19 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for Pearl Therapeutics is Chronic Obstructive Pulmonary Disease with 2 linked trials, and 1 other condition area appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.